31 August 2017
PureTech Health plc
Total Voting Rights and Share Capital - Month End Disclosure
Pursuant to DTR 5.6.1 of the Disclosure Guidance and Transparency Rules:
As at 31 August 2017 the issued share capital of PureTech Health plc comprised 237,429,696 Ordinary shares of one pence each. There were no shares held in treasury.
The total number of voting rights in PureTech Health plc is therefore 237,429,696.
This information may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the immune, nervous, and gastro-intestinal systems by intervening early and addressing the underlying pathophysiology of disease. The Company is advancing a rich pipeline that includes two pivotal or registration studies expected to read out in 2017, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programmes. PureTech Health's growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts, who along with PureTech's experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Contact:
|
PureTech Health |
FTI Consulting |
|
Allison Mead Talbot +1 617 651 3156 |
Ben Atwell, Rob Winder +44 (0) 20 3727 1000 |